Radioactive tracer could reveal breast Cancer's HER2 status without a needle

NCT ID NCT04277338

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial tested a new radioactive tracer called 99mTc-HE3-G3 to see if it can safely and accurately detect HER2 protein in breast cancer tumors using SPECT imaging. Thirty adults with primary breast cancer received one injection of the tracer, followed by scans over 24 hours. The goal was to measure how the tracer spreads in the body and tumors, and to compare imaging results with standard biopsy tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Technetium-99m-labelled designed ankyrin repeat proteins HE3-G3 (99mTc-HE3-G3)
What this could lead to: If successful, this imaging method could help doctors see HER2 levels in breast cancer without needing a biopsy, guiding treatment decisions.
What could go wrong: This is an early Phase 1 trial with only 30 people. It focuses on safety and imaging, not treatment. The method may not be accurate enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BREAST CANCER

Contacts and locations

Locations

TomskNRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.